These findings, together with the regulation of metabolic and inflammatory functions, strongly suggest that FXR is an ideal target for the treatment of hepatic fibrosis, cirrhosis, and portal hypertension (Brunt et al., 2019; Gawrieh et al., 2019; Younossi et al., 2019). This evidence concerns the gene NR1H4 and Hepatic fibrosis.